Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Patients with myeloproliferative neoplasms (MPNs) face significantly higher risks of thrombosis, hemorrhage, and leukemic transformation. This large-scale study highlights the urgent need for strategies to mitigate these severe complications in MPN patients.
Area Of Science
- Hematology
- Oncology
- Epidemiology
Background
- Myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF), are associated with serious complications.
- Large-scale, population-based data on thrombosis, hemorrhage, and leukemic transformation risks in MPN patients are limited.
Purpose Of The Study
- To investigate the risks of thrombosis, hemorrhage, and leukemic transformation in a nationwide cohort of patients with myeloproliferative neoplasms (MPNs).
- To compare these risks between MPN patients and a matched control group.
Main Methods
- A nationwide longitudinal cohort study was conducted using the Korean National Health Insurance System (NHIS) database.
- 11,991 MPN patients were compared with 47,964 age- and sex-matched controls.
- Cox proportional hazards regression was used to estimate risks, with stratified analyses for related factors.
Main Results
- MPN patients exhibited higher risks of arterial thrombosis (aHR 1.695), venous thrombosis (aHR 1.963), and hemorrhage (aHR 1.714) compared to controls.
- The cumulative incidence of leukemic transformation over 10 years was 6.2% in MPN patients, significantly higher than in controls (0.1%).
- Follow-up data over a median of 7.8 years revealed increased event rates for thrombosis, hemorrhage, and leukemia in the MPN cohort.
Conclusions
- Patients with MPNs have a substantially elevated risk of developing thrombosis, hemorrhage, and leukemic transformation.
- These findings underscore the critical need for proactive management strategies to reduce morbidity and mortality in MPN patients.
- Further research and clinical interventions are warranted to mitigate these life-threatening complications.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
The first is the irregular texture of blood vessels, which can...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...